Chart-Typ:
Zeitraum:
| T1 Energy Inc.: T1 Energy Reports Fourth Quarter and Full-Year 2025 Results | AUSTIN, Texas and NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ("T1," "T1 Energy," or the "Company") today reported financial and operating results for the fourth quarter... ► Artikel lesen |
| T1 Energy Inc.: T1 Executes First Sale of Section 45X Tax Credits | AUSTIN, Texas and NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ("T1," "T1 Energy," or the "Company") announced this morning that the Company has completed a $160 million sale... ► Artikel lesen |
| T1 Energy Inc.: Update on T1 Energy FEOC Compliance Efforts | AUSTIN, Texas and NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ("T1," "T1 Energy," or the "Company") announced that today it has concluded a series of transactions with Trina... ► Artikel lesen |
| Niu Technologies Provides First Quarter 2026 Sales Volume Update | BEIJING, April 06, 2026 (GLOBE NEWSWIRE) -- Niu Technologies ("NIU" or "the Company") (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume... ► Artikel lesen |
| Niu Technologies Announces Unaudited Fourth Quarter and Full Year 2025 Financial Results | -- Fourth Quarter Revenues of RMB 676.2 million, down 17.4% year over year -- Fourth Quarter Net Loss of RMB 88.1 million, compared with RMB 72.5 million in the same period of 2024 -- Full Year Revenues... ► Artikel lesen |
| Niu Technologies Provides Fourth Quarter and Full Year 2025 Sales Volume Update | BEIJING, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Niu Technologies ("NIU" or the "Company") (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results | Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally... ► Artikel lesen |
| Weekly Buzz: aTyr Pharma To Meet With FDA, Sangamo Therapeutics Aces Fabry Study, Aquestive Therapeutics' Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GIFTIFY INC finden Sie auf Wallstreet Online.